Literature DB >> 16424979

Polymorphism in the 3'-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy.

Jian-Wei Lu1, Chang-Ming Gao2, Jian-Zhong Wu2, Hai-Xia Cao2, Kazuo Tajima3, Ji-Feng Feng4.   

Abstract

To investigate the relationship between polymorphism in the 3'-untranslated region (3'-UTR) of the thymidylate synthase (TS) gene and sensitivity of gastric cancer to 5-fluorouracil (5-FU)-based chemotherapy, 106 cases of advanced gastric cancer were analyzed. All patients were treated with 5-FU-based chemotherapy; DNA from peripheral blood leukocytes was obtained before therapy. TS 3'-UTR genotypes were detected by PCR-RFLP. Polymorphism in the TS 3'-UTR can be classified into three groups according to the presence or absence of a 6 bp nucleotide fragment: the -6/-6 bp, -6/+6 bp and +6/+6 bp groups. The response rate of the -6/-6 bp and -6/+6 bp groups was found to be significantly higher than the +6/+6 bp group. These results show that the presence of the TS 3'-UTR 6 bp nucleotide fragment can be correlated with the sensitivity of gastric cancer to 5-FU-based chemotherapy, and that the TS 3'-UTR polymorphism profile can be used to guide the choice of 5-FU-based chemotherapy in advanced gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424979     DOI: 10.1007/s10038-005-0339-4

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  20 in total

Review 1.  Developments in the treatment of gastric cancer in Europe.

Authors:  C H Köhne; J A Wils; H J Wilke
Journal:  Oncology (Williston Park)       Date:  2000-12       Impact factor: 2.990

Review 2.  Chemotherapy of carcinoma of the stomach.

Authors:  M Findlay; D Cunningham
Journal:  Cancer Treat Rev       Date:  1993-01       Impact factor: 12.111

3.  Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer.

Authors:  A Calascibetta; D Cabibi; A Martorana; G Sanguedolce; L Rausa; S Feo; G Dardanoni; R Sanguedolce
Journal:  Anticancer Res       Date:  2004 Nov-Dec       Impact factor: 2.480

Review 4.  Status of treatment for advanced gastric carcinoma.

Authors:  James Y Tsai; Howard Safran
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

5.  Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations.

Authors:  S Marsh; E S Collie-Duguid; T Li; X Liu; H L McLeod
Journal:  Genomics       Date:  1999-06-15       Impact factor: 5.736

6.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

7.  Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study.

Authors:  R C Coombes; C E Chilvers; D Amadori; F Medi; G Fountzilas; H Rauschecker; P Vassilopoulos; E P Ferreira; G Vannozzi; J M Bliss
Journal:  Ann Oncol       Date:  1994-01       Impact factor: 32.976

Review 8.  Docetaxel for gastric and esophageal carcinomas.

Authors:  Jaffer A Ajani
Journal:  Oncology (Williston Park)       Date:  2002-06       Impact factor: 2.990

9.  Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer.

Authors:  Sabine Merkelbach-Bruse; Volkmar Hans; Micaela Mathiak; Rosario Sanguedolce; Riccardo Alessandro; Josef Rüschoff; Reinhard Büttner; Farzad Houshdaran; Lucia Gullotti
Journal:  Oncol Rep       Date:  2004-04       Impact factor: 3.906

10.  A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.

Authors:  N K Kim; Y S Park; D S Heo; C Suh; S Y Kim; K C Park; Y K Kang; D B Shin; H T Kim; H J Kim
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860

View more
  14 in total

Review 1.  A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants.

Authors:  Jian-Min Chen; Claude Férec; David N Cooper
Journal:  Hum Genet       Date:  2006-06-29       Impact factor: 4.132

2.  Polymorphisms of thymidylate synthase in the 5'- and 3'-untranslated regions and gastric cancer.

Authors:  Wen Zhuang; Xiao-Ting Wu; Yong Zhou; Guan-Jian Liu; Tai-Xiang Wu; Xun Yao; Liang Du; Mao-Ling Wei
Journal:  Dig Dis Sci       Date:  2008-11-07       Impact factor: 3.199

Review 3.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.

Authors:  D Meulendijks; E A Rozeman; A Cats; K Sikorska; M Joerger; M J Deenen; J H Beijnen; J H M Schellens
Journal:  Pharmacogenomics J       Date:  2016-12-20       Impact factor: 3.550

Review 5.  Genetic variation in microRNA networks: the implications for cancer research.

Authors:  Bríd M Ryan; Ana I Robles; Curtis C Harris
Journal:  Nat Rev Cancer       Date:  2010-06       Impact factor: 60.716

Review 6.  Germline oncopharmacogenetics, a promising field in cancer therapy.

Authors:  Chiara Pesenti; Milena Gusella; Silvia M Sirchia; Monica Miozzo
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

7.  Single nucleotide polymorphisms in microRNA binding sites of oncogenes: implications in cancer and pharmacogenomics.

Authors:  Mayakannan Manikandan; Arasambattu Kannan Munirajan
Journal:  OMICS       Date:  2013-11-28

8.  A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance.

Authors:  Prasun J Mishra; Rita Humeniuk; Pravin J Mishra; Giuseppe S A Longo-Sorbello; Debabrata Banerjee; Joseph R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-08       Impact factor: 11.205

9.  Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer.

Authors:  Qiong Hu; Xuefei Li; Chunxia Su; Xiaoxia Chen; Guanghui Gao; Jie Zhang; Yinmin Zhao; Jiayu Li; Caicun Zhou
Journal:  Exp Ther Med       Date:  2012-09-28       Impact factor: 2.447

10.  Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC.

Authors:  Xia Wang; Yadi Wang; Yue Wang; Jian Cheng; Yanyun Wang; Minwen Ha
Journal:  J Biomed Sci       Date:  2013-01-25       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.